ABBV-295 vs cagrilintide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
ABBV-295
Developed by AbbVie under a licence from Gubra
NCT06144684 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Safety - Adverse Events (AE) incidence" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2026 · NCT07514260 (registry estimate)
Reported efficacy
Safety - Adverse Events (AE) incidence (from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C); Safety - changes in vital signs (from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C); Safety - Safety laboratory parameters (From baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C): Two-part first-in-human phase 1 study of subcutaneous ABBV-295, a long-acting amylin analog: ABBV-295 demonstrated a favorable tolerability profile at all evaluated dose levels and no serious adverse events were reported. Treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 with weekly dosing. (not_applicable)
Result source: NCT06144684
cagrilintide
Developed by Novo Nordisk
NCT03856047 · Phase 2 · completed
The trial randomized participants to five active doses, a pooled placebo, and an active liraglutide comparator arm, with quadruple-blinding (participant, care provider, investigator, and outcomes assessor all masked) and roughly 100 participants per arm. The primary endpoint, percent change in body weight at 26 weeks, is the regulator-accepted physiological measure for obesity trials, and every cagrilintide dose showed a statistically significant weight-loss advantage over placebo (p-values ranging from 0.0002 to <.0001), so the primary comparison was clearly met in the favorable direction.
Next expected readout: January 2027 · NCT07411560 (registry estimate)
Reported efficacy
Change in Body Weight (%) (From baseline (week 0) to week 26): Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2) (met)
Result source: NCT03856047
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ABBV-295 | cagrilintide |
|---|---|---|
| Body weight, % change | —Not reported | -10.8% vs -3%−7.8 vs placeboNCT038560474 other results
|
| Weight loss of 5% or more | —Not reported | 88.7% vs 30.9%+57.8 vs placeboNCT038560474 other results
|
| Weight loss of 10% or more | —Not reported | 53.5% vs 10.4%+43.1 vs placeboNCT038560474 other results
|
| Waist circumference, change (cm) | —Not reported | -9.5 vs -3.4−6.1 vs placeboNCT038560474 other results
|
Body weight, % change
- ABBV-295
- —Not reported
- cagrilintide
- -10.8% vs -3%−7.8 vs placeboNCT03856047
4 other results
- -9.5% vs -3% NCT03856047
- -8.5% vs -3% NCT03856047
- -6.9% vs -3% NCT03856047
- -6.1% vs -3% NCT03856047
Weight loss of 5% or more
- ABBV-295
- —Not reported
- cagrilintide
- 88.7% vs 30.9%+57.8 vs placeboNCT03856047
4 other results
- 74.1% vs 30.9% NCT03856047
- 75.8% vs 30.9% NCT03856047
- 62.0% vs 30.9% NCT03856047
- 57.5% vs 30.9% NCT03856047
Weight loss of 10% or more
- ABBV-295
- —Not reported
- cagrilintide
- 53.5% vs 10.4%+43.1 vs placeboNCT03856047
4 other results
- 44.0% vs 10.4% NCT03856047
- 35.8% vs 10.4% NCT03856047
- 24.1% vs 10.4% NCT03856047
- 15.3% vs 10.4% NCT03856047
Waist circumference, change (cm)
- ABBV-295
- —Not reported
- cagrilintide
- -9.5 vs -3.4−6.1 vs placeboNCT03856047
4 other results
- -8.1 vs -3.4 NCT03856047
- -7.7 vs -3.4 NCT03856047
- -6.2 vs -3.4 NCT03856047
- -6.2 vs -3.4 NCT03856047
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ABBV-295: no structured comparison results are available for Obesity.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ABBV-295: 0 of 4 rows · cagrilintide: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | cagrilintide |
|---|---|
| Dropout rate | 6.9%4.5 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more results1%2.4 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 3.9%1.2 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 3%0.6 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 4%0.3 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 |
| Discontinued due to AEs | —4.5 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more results—2.4 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 —1.2 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 —0.6 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 —0.3 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 |
| Serious AEs | 4%4.5 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more results2.9%2.4 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 6.9%1.2 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 2%0.6 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 5.9%0.3 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 |
| Most frequent reported AEs | 4.5 mg nausea 46.5% (placebo 17.8%) constipation 20.8% (placebo 6.9%) fatigue 19.8% (placebo 3%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more results2.4 mg nausea 31.4% (placebo 17.8%) diarrhoea 17.6% (placebo 8.9%) constipation 16.7% (placebo 6.9%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 1.2 mg nausea 36.3% (placebo 17.8%) nasopharyngitis 12.7% (placebo 9.9%) headache 10.8% (placebo 11.9%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 0.6 mg nausea 27% (placebo 17.8%) diarrhoea 10% (placebo 8.9%) constipation 9% (placebo 6.9%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 0.3 mg nausea 19.8% (placebo 17.8%) diarrhoea 14.9% (placebo 8.9%) constipation 10.9% (placebo 6.9%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
cagrilintide
show 4 more results
show 4 more results
show 4 more results
show 4 more results
show 4 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-295's landscape · cagrilintide's landscape